Is there a German origin for Lukapani/Lukapali?

Rucaparib/Rucaparib is a drug developed by the British biotechnology company Clovis Oncology. Clovis Oncology was founded in 2009 and is headquartered in Colorado, USA, not Germany. Rucapanib is a PARP inhibitor drug that inhibits the growth of cancer cells by interfering with DNA repair mechanisms. It has been approved in several countries to treat ovarian cancer as well as prostate cancer, among other tumor types. The development and production of Lukapa does not come from Germany, but from Clovis Oncology's research and manufacturing bases around the world.

In Germany, rucaparib is indicated for the treatment of high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in women if these cancers have progressed or recurred despite prior platinum-based chemotherapy. In this case, the drug can only be given to women with BRCA gene mutations. Rucaparib is approved only for patients who have responded to platinum-based chemotherapy. Ovarian cancer often goes undetected for long periods of time because there are often no symptoms or only nonspecific symptoms. By the time a tumor is discovered, it's usually at an advanced stage. Advanced ovarian cancer is surgically removed and treated with chemotherapy. If relapse occurs after treatment, full recovery is usually no longer possible. The goal of treatment is to stop the cancer from getting worse and reduce symptoms for as long as possible. In this case, rucapanib was used to inhibit several proteins that influence tumor growth.

Rucaparib is available in three different strengths of tablets: 200, 250 and 300 mg. The recommended dose is 600 mg of rucaparib twice daily. Dosage can be adjusted based on any side effects that occur and blood test results. Stop treatment if serious side effects occur or the cancer progresses.